Cancer vaccines represent a promising strategy to induce specific and durable immune responses against tumor antigens (TAs), which are mainly proteins overexpressed in tumor tissue and play a central role in tumor initiation, progression and metastasis. Cancer vaccines have many superior advantages, including minimal non-specific effects, relative non-toxicity, and induction of persistent immunological memory and so on. Compared with standard chemo- and immunotherapies, cancer vaccines have reduced adverse reactions, higher therapeutic efficacy as well as lower costs. Alfa Cytology is a leading custom service provider in pancreatic cancer (PC) vaccine research and development. We are committed to providing the best service in therapeutic vaccine development for PC, including whole-cell PC vaccines, peptide-based PC vaccines, dendritic cell-based PC vaccines, and so on.
Fig. 1 The killing function to metastasis pancreatic cancer (PC) of Cytotoxic T cells is promoted by vaccinations. (Luo, Wenhao, et al., 2020)
Overview of therapeutic vaccines for PC
Due to its systemic and aggressive nature, complex mutational environment, desmoplastic stroma, and effective immunosuppressive tumor microenvironment (TME), PC is highly resistant to chemotherapy and radiotherapy, with poorer outcomes compared to other solid tumors and lack of effective therapeutic treatments to cure them. Therefore, there is an urgent need to develop new, effective and well-tolerated therapies for the treatment of this disease, and immunotherapy is an obvious area to explore. In the broad field of immunotherapy, cancer vaccines are a promising approach because of their effectiveness, safety and low cost. To date, a multitude of vaccines have been studied in PC, involving whole-cancer cells, dendritic cells (DCs), specific peptides, nucleic acids, and so on. As for antigen targets, mutated KRAS, mucin-1 (MUC1), mesothelin, Wilms' tumor 1 (WT1), and carcinoembryonic antigen (CEA) are the most attractive targets.
There are several types of vaccine strategies for PC, including,
-Dendritic cell-based vaccines
-Peptide and protein vaccines
-Whole-cancer cell-based vaccines
-DNA and mRNA-based vaccines
-Listeria-based vaccines
-Recombinant virus-based vaccines
The service offering at Alfa Cytology
We have an in-depth understanding of the tumor immunological profile of PC, particularly intra-tumor heterogeneity, tumor-microenvironment crosstalk, and microenvironmental instability. Therefore, we can help our clients to achieve precise and feasible development applications of PC vaccines and improve the efficacy and safety of related vaccines. We are able to provide a range of services, specifically including,
- Whole-cancer cell vaccine development for PC
- iPSC-based vaccine development for PC
- Dendritic cell-based vaccine development for PC
- Peptide-based vaccine development for PC
- Custom mRNA vaccine development for PC
- DNA vaccine development for PC
As one of the leading service providers in the field of PC research and drug development, we continuously challenge ourselves and strive to offer our customers the finest service. If you are interested in learning more about our PC vaccine development services, please feel free to contact us. We look forward to working with you!
References
- Chi, Jeffrey, et al. "Recent advances in immunotherapy for pancreatic cancer." Journal of Cancer Metastasis and Treatment 6 (2020): 43.
- Mucciolo, Gianluca, et al. "The dark side of immunotherapy: Pancreatic cancer." Cancer Drug Resistance 3.3 (2020): 491.
- Luo, Wenhao, et al. "Novel therapeutic strategies and perspectives for metastatic pancreatic cancer: vaccine therapy is more than just a theory." Cancer cell international 20.1 (2020): 1-10.